Minimization of potential hERG liability in histamine H3 receptor antagonists

Inflammation Research

Volumn 57, Issue SUPPL. 1, 2008, Pages

  Black, L A ^a   Liu, H ^a   Diaz, G J ^a   Fox, G B ^a   Browman, K E ^a   Wetter, J ^a   Marsh, K C ^a   Miller, T R ^a   Esbenshade, T A ^a   Brioni, J ^a   Cowart, M D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; BENZOFURAN DERIVATIVE; CYCLOBUTANE DERIVATIVE; DOFETILIDE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; NAPHTHALENE DERIVATIVE; POTASSIUM CHANNEL HERG; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BINDING AFFINITY; BINDING ASSAY; BRAIN TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; MALE; NEWBORN; NONHUMAN; RADIOASSAY; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BENZOFURANS; CYCLOBUTANES; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MOLECULAR STRUCTURE; NAPHTHALENES; RADIOLIGAND ASSAY; RATS; RECEPTORS, HISTAMINE H3; TRANS-ACTIVATORS;

EID: 43249111185     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-0622-2     Document Type: Conference Paper

References (8)

1. Kr potassium channel. Cell 1995; 81: 299-307.
2. El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol 2003; 18: 6-13.
3. 3 receptor ligands and their therapeutic applications. US 6,969,730 B2, issued November 29, 2005.
4. Altenbach RJ, Black LA, Chang SJ, Cowart MD, Faghih R, Gfesser GA et al. Bicyclic-substituted amines as histamine-3 receptor ligands. US 7,153,889 B2, issued December 26, 2006.
5. Liu H, Hancock AA, Cowart MD. Cyclobutyl amine derivatives. WO 2006/132914 A2, published December 14, 2006.
6. o. J Pharmacol Toxicol Methods 2004; 50: 187-99.
7. 3 Receptor Antagonist with Drug-Like Properties. J Pharmacol Exp Ther 2005; 313: 165-75.
8. 3R) antagonists in several animal models. Inflamm Res 2004: 53: S49-S50.